Publication for GBA and GLB1

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	GBA	glucosylceramidase beta	2629			[link]
hsa	GLB1	galactosidase beta 1	2720

Pubmed ID	Priority	Text
25107912	0.98	beta-galactosidase (beta-Gal), alpha-Galactosidase (alpha-Gal), and beta-glucocerebrosidase (beta-GCase) were measured in blood sera of 3-month-old wild-type (+/+) and nym/+ mice.
	0.98	beta-galactosidase (beta-Gal), alpha-galactosidase (alpha-Gal), and beta-glucocerebrosidase (beta-GCase) were measured in whole brain homogenates of wild-type (+/+) and nym (nym/nym) mice (4 months of age).
29559523	0.98	acid beta galactosidase (GBA) that cleaves beta-glucose is entirely dependent on SapC for activity.
29333001	0.97	GBA1, beta-Gal, beta-Hex, sialidase Neu3, and SMase.
	0.96	GBA1, GBA2, beta-Gal, and beta-Hex activities at cell surface of CuFi-1 cells under identical experimental conditions.
	0.96	beta-Gal, GBA1, beta-Hex, and SMase were found to be increased in DRM isolated from infected cells.
	0.93	GBA1 activity is 3857 +- 635 pmoles/mg/h, increasing to 10,408 +- 690 pmoles/mg/h in CuFi-1-GBA2, whereas beta-Gal increased in CuFi-1-GBA2 compared to CuFi-1 or mock cells (Figure 5).
	0.88	GBA1, GBA2, beta-Gal, and beta-Hex) in CuFi-1 cells.
	0.64	beta-galactosidase (beta-Gal), beta-hexosaminidase (beta-Hex), sialidase Neu3, beta-glucocerebrosidase GBA1, and the nonlysosomal beta-glucosylceramidase GBA2 have already been identified.
31603917	0.97	GLB1 (FC 32,9), GLMN (FC 15,2), ADK (FC 10,5), PSMG4 (FC 8,2), PSAP (FC 6,5), PHPT1 (FC 6,2), showed higher levels in GCB DLBCL cases (Fig 1).
	0.97	GCB and for the 6 proteins (from low to high fold change)(PHPT1 (FC 6,2), PSAP (FC 6,5), PSMG4 (FC 8,2), ADK (FC 10,5), GLMN (FC 15,2), GLB1 (FC 32,9)), with higher expression in GCB DLBCL with on the Y-axis SILAC ratio (FC, fold change).
29343884	0.97	beta-galactosidase, and beta-glucocerebrosidase were quantified in untreated and VD3-treated HN9.10e cells.
28687494	0.96	GBA, glucosylceramidase beta; A-CD, acid ceramidase; GCS, glucosylceramide synthase; GCase, glucosylceramidase; LCS, lactosylceramide synthase; beta-GS, beta-galactosidase; STs, sialyltransferases; GTs, glucosyltransferases; SK, sphingosine kinase; S1PP, sphingosine-1-phosphate phosphatase; S1PL, sphingosine-1-phosphate lyase.
25378395	0.95	beta-galactosidase and no effect on beta-glucocerebrosidase.
	0.90	beta-glucocerebrosidase and beta-galactosidase were assayed by flow cytometry using the substrates 5-(pentafluorobenzoylamino)fluorescein di-beta-d-glucopyranoside and C12FDG, respectively.
	0.70	beta-glucocerebrosidase and beta-galactosidase.
27378698	0.95	beta-galactosidase and the protein expression levels of mature cathepsin D protein and LAMP1 were all significantly increased in GBA1 KD cells (Figure 4B-D).
	0.86	beta-Galactosidase was significantly increased in Gba1 HET and Gba1 KO compared to Gba1 WT (n = 5).
24436092	0.95	beta-glucocerebrosidase, beta-mannosidase, beta-hexosaminidase, and beta-galactosidase were measured with established enzymatic assays, while alpha-synuclein and tau biomarkers were evaluated with immunoassays.
32071839	0.95	GBA, GLB1, HEXA, HEXB, GM2A, PSAP, SMPD1), MPS (IDUA, SGSH, NAGLU, HGSNAT, GNS, ARSB, GUSB) and mucolipidoses (GNPTAB, GNPTG), as well as glycoproteinoses (MAN2B1, FUCA1, NEU1, CTSA), lipid storage diseases (LIPA), post-translational modification defects (SUMF1), and lysosomal integral protein disorders (LAMP2, NPC1, NPC2, SCARB2, SLC17A5).
30344007	0.94	GBA1, beta-galactosidase, and beta-hexosaminidase were similar in patients and controls.
26175280	0.93	beta-galactosidase, and beta-N-acetylglucosaminidase have been applied to generate N-glycans with exposed mannose residues on recombinant glucocerebrosidase (imiglucerase).
27228111	0.93	acid beta-glucosidase, 4-methylumbelliferyl beta-D-galactopyranoside (MUGal) for beta-galactosidase or similar MUG type substrates for other glycosidase enzymes typically employ lysis assay methods or other cell disruption protocols, such that their use in live cell analysis is limited.
27755597	0.93	beta-galactosidase, beta-glucocerebrosidase and beta-mannosidase) only exhibited limited variations compared to HYAL1, cathepsin K and TRAP (Table 1), confirming that only a subset of acid hydrolases are upregulated upon osteoclastogenesis.
30308956	0.93	beta-galactosidase (beta-gal), beta-glucocerebrosidase (GCase), and the non-lysosomal beta-glucosylceramidase (NLGase).
26609196	0.92	glucocerebrosidase-1, glucocerebrosidase-2, hexosaminidase, galactosylceramidase, alpha-galactosidase, and beta-galactosidase activities were also elevated in those patients.
31703585	0.92	GBA, beta-hexosaminidase and beta-galactosidase activities have been reported in CSF of PD-GBA patients, but also sporadic PD patients.
25294702	0.74	GLB1, GBA, GLA, UGCG, HEXB) with generally comparable expression levels among the cell lines, except for the UGCG gene which was expressed at considerably higher levels in both HOSE cell lines compared with the ovarian cancer cell lines.
28191815	0.74	GBA1/GBA2, beta-galactosidase, and beta-hexosaminidase increased significantly (Table 1).
28792770	0.59	GBA, glucocerebrosidase, 4MU-beta-glucoside; GLB1, beta-galactosidase, 4MU-beta-galactoside; GUSB, beta-glucuronidase, 4MU-beta-glucuronide; HEX total, hexosaminidase total, 4MU-2-acetamido-2-deoxy-beta-d-glucopiranoside; HEXA, hexosaminidase A, 4MU-2-acetamido-2-deoxy-6-sulfo-beta-d-glucopiranoside; LGMN, legumain, Z-Ala-Ala-Asn-AMC; LIPA, acid lipase, 4MU-oleate* or 4MU-palmitate**; MAN2B1, alpha-mannosidase, 4MU-alpha-mannoside; MANBA, beta-mannosidase, 4MU-beta-mannoside; NAGA, alpha-N-acetylgalactosaminidase, 4-MU-2-acetamido-2-deoxy-alpha-d-galactopiranoside; NAGLU, alpha-N-acetylglucosaminidase, 4MU-alpha-N-acetyl-glucosaminide; PPT1, palmitoyl protein thioesterase 1, 4MU-6-thiopalmitoyl-8-glucoside; TPP1, tripeptidylpeptidase 1, Ala-Ala-Phe-AMC.
24269151	0.51	imiglucerase, Cerezyme) is used that is in vitro deglycosylated, using alpha-neuraminidase, beta-galactosidase, and beta-N-acetylglucosaminidase, to expose terminal mannose residues, which improves its targeting and internalization.
29735433	0.51	beta-galactosidase are reported in human neurons from PD patients carrying a GBA mutation.